ProQR Therapeutics N.V. PRQR
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 19.49% | -23.68% | -12.33% | -12.02% | 7.57% |
| Total Other Revenue | -89.97% | -64.12% | -30.10% | 8.93% | 79.24% |
| Total Revenue | 15.32% | -25.02% | -12.91% | -11.45% | 9.23% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 15.32% | -25.02% | -12.91% | -11.45% | 9.23% |
| SG&A Expenses | 10.50% | 25.80% | 15.40% | 6.19% | 5.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.29% | 22.60% | 24.71% | 28.46% | 34.85% |
| Operating Income | -9.65% | -50.77% | -48.82% | -53.21% | -49.11% |
| Income Before Tax | -13.39% | -61.93% | -57.52% | -79.90% | -85.87% |
| Income Tax Expenses | 48.53% | 110.03% | 110.19% | 109.87% | 108.12% |
| Earnings from Continuing Operations | -13.41% | -63.07% | -58.70% | -81.40% | -87.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.41% | -63.07% | -58.70% | -81.40% | -85.44% |
| EBIT | -9.65% | -50.77% | -48.82% | -53.21% | -49.11% |
| EBITDA | -9.72% | -54.11% | -52.79% | -57.46% | -53.02% |
| EPS Basic | -4.72% | -45.03% | -30.70% | -42.17% | -53.70% |
| Normalized Basic EPS | -4.65% | -43.84% | -29.67% | -25.82% | -25.74% |
| EPS Diluted | -3.26% | -45.26% | -33.13% | -44.78% | -57.29% |
| Normalized Diluted EPS | -4.65% | -43.84% | -29.67% | -25.82% | -25.74% |
| Average Basic Shares Outstanding | 8.75% | 14.49% | 22.36% | 27.37% | 20.37% |
| Average Diluted Shares Outstanding | 8.75% | 14.49% | 22.36% | 27.37% | 20.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |